Equity Overview
Price & Market Data
Price: $5.45
Daily Change: $0.00 / 0.00%
Daily Range: $5.06 - $5.51
Market Cap: $981,479,104
Daily Volume: 4,366,981
Performance Metrics
1 Week: 2.25%
1 Month: -4.22%
3 Months: 1.49%
6 Months: 62.20%
1 Year: 222.5%
YTD: 1.49%
Company Details
Employees: 39
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.